Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week High - Still a Buy?

Key Points

• Kiniksa Pharmaceuticals International reached a new 52-week high of $34.46 during trading, with a closing price of $34.23.
• Analysts have raised their price targets for Kiniksa, with Jefferies Financial Group increasing theirs to $54.00 and a consensus price target now set at $41.17.
• The company reported quarterly earnings of $0.23 per share, exceeding estimates, and had revenue of $156.80 million for the quarter.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $34.46 and last traded at $34.23, with a volume of 151068 shares changing hands. The stock had previously closed at $33.38.

Wall Street Analyst Weigh In

Several analysts recently issued reports on KNSA shares. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

The stock has a market cap of $2.50 billion, a P/E ratio of 843.96 and a beta of 0.14. The stock has a fifty day simple moving average of $29.78 and a 200-day simple moving average of $25.49.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In related news, insider John F. Paolini sold 29,325 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total transaction of $954,528.75. Following the sale, the insider owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Sanj K. Patel sold 62,116 shares of the business's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $27.33, for a total value of $1,697,630.28. Following the sale, the chief executive officer owned 96,674 shares in the company, valued at $2,642,100.42. This represents a 39.12% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 674,849 shares of company stock worth $21,144,188. 53.48% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN raised its holdings in Kiniksa Pharmaceuticals International by 54.7% during the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company's stock worth $417,000 after purchasing an additional 7,463 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $3,955,000. Barclays PLC raised its stake in Kiniksa Pharmaceuticals International by 11.2% during the fourth quarter. Barclays PLC now owns 71,896 shares of the company's stock worth $1,423,000 after buying an additional 7,267 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Kiniksa Pharmaceuticals International by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after buying an additional 29,300 shares during the period. Finally, MetLife Investment Management LLC boosted its position in Kiniksa Pharmaceuticals International by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after acquiring an additional 1,374 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.